SCHEMBL6896808

SCHEMBL6896808

CCOC(=O)C(CSc1ccccc1)NC(=O)CC(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.48
MTNR1B P49286 3/20 0.48
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 5/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
ADORA1 P30542 1/20 0.40
PSMB5 P28074 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 1/20 0.39
PLA2G10 O15496 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6896805 1.00 MTNR1A (0.48) MTNR1AMTNR1BMAPTNPSR1L3MBTL1
Hydrochloric Acid SCHEMBL6898788 0.79 MTNR1A (0.44) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL6898792 0.79 MTNR1A (0.44) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
SCHEMBL12961640 0.77 L3MBTL1 (0.51) MAPTL3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL2235605 0.76 SMN1; SMN2 (0.45) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
SCHEMBL6221210 0.73 MAOA (0.53) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
SCHEMBL7651607 0.73 MAOA (0.53) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
SCHEMBL2237332 0.73 MAOA (0.53) MTNR1AMTNR1BMAPTL3MBTL1ALDH1A1
SCHEMBL21792020 0.73 PPID (0.48) MAPTNPSR1L3MBTL1GAAKMT2A
SCHEMBL21777305 0.73 PPID (0.48) MAPTNPSR1L3MBTL1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH MTNR1A 1511/4885MTNR1B 1529/4885MAPT 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.